Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: A 12-Month Open-Labeled Trial.

被引：0
作者：
Mok, Chi Chiu [1 ]
Chan, Pak To [1 ]
Ho, Ling Yin [1 ]
Yu, Ka Lung [1 ]
机构：
[1] Tuen Mun Hosp, Hong Kong, Hong Kong, Peoples R China
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1414
引用
收藏
页码：S608 / S609
页数：2
相关论文
共 48 条
[41]   Preliminary results of an open label randomised clinical trial comparing mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis (LN). [J].
Flores-Suárez, LF ;
Villa, AR .
ARTHRITIS AND RHEUMATISM, 2004, 50 (09) :S414-S415
[42]   EFFICACY AND SAFETY OF MULTI-TARGET THERAPY USING A COMBINATION OF CYCLOPHOSPHAMIDE AND TACROLIMUS IN PATIENTS WITH REFRACTORY LUPUS NEPHRITIS: A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL STUDY OF 13 PATIENTS [J].
Sakai, R. ;
Shibata, A. ;
Chino, K. ;
Kondo, T. ;
Okuyama, A. ;
Takei, H. ;
Amano, K. .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 :1077-1077
[43]   De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial [J].
Huh, Kyu Ha ;
Lee, Jae Geun ;
Ha, Jongwon ;
Oh, Chang-Kwon ;
Ju, Man Ki ;
Kim, Chan-Duck ;
Cho, Hong Rae ;
Jung, Cheol Woong ;
Lim, Beom Jin ;
Kim, Yu Seun .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (08) :1415-1424
[44]   A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis [J].
Stratta, RJ ;
Alloway, RR ;
Hodge, E ;
Lo, A .
CLINICAL TRANSPLANTATION, 2002, 16 (01) :60-68
[45]   Acalabrutinib in Chinese Patients (Pts) with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): 12-Month Efficacy and Safety Results from an Open-Label, Multicenter Phase 1/2 Trial [J].
Yang, Shenmiao ;
Huang, Haiwen ;
Zhou, Keshu ;
Zhao, Xielan ;
Han, Yanqiu ;
Li, Lindong ;
Butturini, Anna ;
Wang, Yujie ;
Liu, Xiaofeng ;
Lai, Peiqiong ;
Li, Jianyong .
BLOOD, 2023, 142
[46]   Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial [J].
Claudia Sommerer ;
Barbara Suwelack ;
Duska Dragun ;
Peter Schenker ;
Ingeborg A. Hauser ;
Björn Nashan ;
Friedrich Thaiss .
Trials, 17
[47]   Design rationale of the ATHENA study - A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial [J].
Sommerer, Claudia ;
Suwelack, Barbara ;
Dragun, Duska ;
Schenker, Peter ;
Hauser, Ingeborg A. ;
Nashan, Bjoern ;
Thaiss, Friedrich .
TRIALS, 2016, 17
[48]   Ledipasvir/Sofosbuvir Fixed-Dose Combination (LDV/SOF FDC) for 8 Weeks for Treatment-NaIve, Non-cirrhotic Hepatitis C Genotype 6 (HCV-6) and for 12 Weeks for Those With Cirrhosis and/or Prior Treatment Failure: An Open-Labeled Clinical Trial [J].
Nguyen, Mindie H. ;
Trinh, Huy N. ;
Do, Son T. ;
Nguyen, Thuan .
HEPATOLOGY, 2016, 64 :463A-463A
12345